Investor FAQ

Show all

Juniper Pharmaceuticals changed its name from Columbia Laboratories on April 13, 2015 to better reflect the Company’s strategy of drug development. As part of this transition, Molecular Profiles, a wholly owned subsidiary of Juniper Pharmaceuticals, changed its name to Juniper Pharma Services.
Our Common Stock has traded on the Nasdaq Global Market since February 13, 2004. In keeping with the Company’s name change, the ticker symbol changed to JNP from CBRX on April 13, 2015. The Company previously traded on the American Stock Exchange under the symbol COB.
Stock certificates bearing the Company’s former name, Columbia Laboratories, Inc., will remain valid. Please note that our ticker symbol has changed to JNP from CBRX.
Juniper Pharmaceuticals, formerly known as Columbia Laboratories, Inc., became a Delaware corporation in 1986.
PricewaterhouseCoopers, LLP
American Stock Transfer & Trust Company, LLC
59 Maiden Lane
New York, New York 10038
T: (800) 937-5449

A transfer agent maintains stock registries for their client companies such as Juniper Pharmaceuticals. They issue and cancel stock certificates, process and pay dividends, administer dividend reinvestment programs, resolve issues arising from lost or stolen certificates, and answer questions from shareholders about their accounts.
Questions regarding stock transfer requirements, lost certificates, and changes of address should be directed to
American Stock Transfer & Trust Company, LLC
59 Maiden Lane
New York, New York 10038
T: (800) 937-5449
A 1-for-8 reverse split of our Common Stock, par value $0.01 per share, was effective when the market opened on August 9, 2013. The reverse stock split reduced the number of issued and outstanding shares of Common Stock from approximately 87,737,329 to approximately 10,967,112.
The CUSIP number for the new Common Stock outstanding after the ticker symbol changed to JNP on April 13, 2015, is 48203L107.
We have never declared or paid a cash dividend on our common stock, and expects that our earnings will continue to be retained for use in the operation and expansion of our business.
Juniper Pharmaceuticals’ fiscal year ends on December 31st each year.
The 2017 Annual Meeting of Shareholders was held on Friday, June 30, 2017. A 2018 meeting date has not been set.
For information about the Company, please contact us at IR@juniperpharma.com . To receive press releases, notice of SEC filings and other alerts by email, click here.
Juniper Pharma Services, formerly known as Molecular Profiles, is a wholly owned subsidiary of Juniper Pharmaceuticals based in the United Kingdom. Please visit http://www.juniperpharma.com/pharma-services/ or contact enquiry@juniperpharma.com.